Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 2/3 1Phase 1 1

Status

Unknown 2Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 6

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Leukemia, Myeloid, Acute 150Leukemia 67Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Leukemia, Myelomonocytic, Acute 26Leukemia, Monocytic, Acute 26Myelodysplastic Syndromes 24Leukemia, Erythroblastic, Acute 23Leukemia, Megakaryoblastic, Acute 22Congenital Abnormalities 21Leukemia, Promyelocytic, Acute 13Leukemia, Myelomonocytic, Chronic 12Anemia, Refractory, with Excess of Blasts 12Recurrence 8Myeloproliferative Disorders 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Lymphoma 7Leukemia, Myeloid, Chronic-Phase 7Leukemia, Eosinophilic, Acute 7Leukemia, Biphenotypic, Acute 7Leukemia, Basophilic, Acute 6Carcinoma, Hepatocellular 6Blast Crisis 6Neoplasm, Residual 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Neutropenia 3Neoplasms, Plasma Cell 3Lymphoma, Large-Cell, Immunoblastic 3

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 124Nivolumab 85pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 43Leucovorin 40tremelimumab 37camrelizumab 37Radiofrequency Ablation 37Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28cabozantinib 26Hepatectomy 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × Idarubicin × Clear all
NCT03727633 2026-03-31

LIDA-BII

University Hospital, Montpellier

Phase 2 Terminated
44 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06492408 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06482801 2024-07-01

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05280444 2022-12-29

Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma

Zhongda Hospital

Phase 2/3 Unknown
216 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05053386 2021-09-22

Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma

Zhejiang Cancer Hospital

Phase NA Unknown
186 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01040559 2013-01-09

Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas

Centre Hospitalier Universitaire Dijon

Phase 1 Completed
18 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡